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Abstract
Background: Results of the Women's Health Initiative Memory Study (WHIMS) raised concerns
regarding the timing and formulation of hormone interventions. Conjugated equine estrogens
(CEE), used as the estrogen therapy in the WHIMS trial, is a complex formulation containing
multiple estrogens, including several not secreted by human ovaries, as well as other biologically
active steroids. Although the full spectrum of estrogenic components present in CEE has not yet
been resolved, 10 estrogens have been identified. In the present study, we sought to determine
which estrogenic components, at concentrations commensurate with their plasma levels achieved
following a single oral dose of 0.625 mg CEE (the dose used in the WHIMS trial) in women, are
neuroprotective and whether combinations of those neuroprotective estrogens provide added
benefit. Further, we sought, through computer-aided modeling analyses, to investigate the potential
correlation of the molecular mechanisms that conferred estrogen neuroprotection with estrogen
interactions with the estrogen receptor (ER).
Results: Cultured basal forebrain neurons were exposed to either β-amyloid25–35 or excitotoxic
glutamate with or without pretreatment with estrogens followed by neuroprotection analyses.
Three indicators of neuroprotection that rely on different aspects of neuronal damage and viability,
LDH release, intracellular ATP level and MTT formazan formation, were used to assess
neuroprotective efficacy. Results of these analyses indicate that the estrogens, 17α-estradiol, 17β-
estradiol, equilin, 17α-dihydroequilin, equilinen, 17α-dihydroequilenin, 17β-dihydroequilenin, and
∆8,9-dehydroestrone were each significantly neuroprotective in reducing neuronal plasma
membrane damage induced by glutamate excitotoxicity. Of these estrogens, 17β-estradiol and ∆8,9-
dehydroestrone were effective in protecting neurons against β-amyloid25–35-induced intracellular
ATP decline. Coadministration of two out of three neuroprotective estrogens, 17β-estradiol,
equilin and ∆8,9-dehydroestrone, exerted greater neuroprotective efficacy than individual
estrogens. Computer-aided analyses to determine structure/function relationships between the
estrogenic structures and their neuroprotective activity revealed that the predicted intermolecular
interactions of estrogen analogues with ER correlate to their overall neuroprotective efficacy.
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Conclusion: The present study provides the first documentation of the neuroprotective profile
of individual estrogens contained within the complex formulation of CEE at concentrations
commensurate with their plasma levels achieved after an oral administration of 0.625 mg CEE in
women. Our analyses demonstrate that select estrogens within the complex formulation of CEE
contribute to its neuroprotective efficacy. Moreover, our data predict that the magnitude of
neuroprotection induced by individual estrogens at relatively low concentrations may be clinically
undetectable and ineffective, whereas, a combination of select neuroprotective estrogens could
provide an increased and clinically meaningful efficacy. More importantly, these data suggest a
strategy for determining neurological efficacy and rational design and development of a composition
of estrogen therapy to alleviate climacteric symptoms, promote neurological health, and prevent
age-related neurodegeneration, such as AD, in postmenopausal women.
Background
Multiple factors have been hypothesized as potential con-
tributors to the disparity between observational studies,
which found that estrogen/hormone therapy (ET/HT) is
associated with improved cognitive function and/or
reduced risk (20–50%) of developing Alzheimer's disease
(AD) in postmenopausal women [1-6], and the rand-
omized double blind clinical trial, Women's Health Initi-
ative Memory Study [7-10], or trials of ET/HT in women
with existing AD [11-14], where ET/HT showed no benefit
and in some instances adverse outcomes on neurological
health in postmenopausal women. Prime among those
factors are the temporal parameters of ET/HT intervention
and the ET/HT formulation.
Using a prevention model paradigm in which cultured
primary neurons were treated with conjugated equine
estrogens (CEE) prior to exposure to degenerative insults
associated with AD, our earlier work demonstrated that
CEE significantly protected neurons against toxic insults-
induced cell death [15]. In a treatment model paradigm,
in which primary neurons were first exposed to β-
amyloid25–35 followed by CEE treatment, neurons treated
with CEE had a slower rate of degeneration but were not
protected against β-amyloid25–35-induced cell death [15].
Our in vitro model systems that simulate prevention ver-
sus treatment modes of estrogen exposure indicate a
healthy cell bias of estrogen action in neurons [16,17],
and they provide us a lens through which to view the clin-
ical data from both observational studies and trials. That
is, women who received ET/HT at the time of menopause,
in a prevention mode before extensive age-associated
degeneration occurs, exhibited improved cognitive func-
tion and a lower risk of developing AD than women who
had never received ET/HT, which is consistent with most
observational analyses [1-6,18-21]. In contrast, when
women received ET/HT in their 60's or 70's, when age-
associated insults have already occurred in some women,
or following the onset of AD, ET/HT had no benefit to or
even exacerbated the degenerative state, as demonstrated
in a number of clinical trials, including the WHIMS [7-
14]. These analyses suggest that ET/HT can be effective in
preventing rather than treating age-related neuronal
decline and degeneration.
Timing of ET/HT intervention is paralleled by the crucial
issue of ET/HT formulation. First, the question of which
progestin to use in ET/HT remains unresolved. Results of
the WHIMS CEE plus medroxyprogesterone acetate
(MPA) trial indicated an increased risk (hazard ratio:
2.05) of developing dementia [8,10], whereas the CEE
alone trial showed no statistically significant benefit or
detriment, although there was a trend towards increased
risk (hazard ratio: 1.49) of developing dementia [7,9].
The difference in severity of adverse outcomes between
the CEE plus MPA trial and CEE alone trial suggests that
the addition of MPA to the estrogen formulation exacer-
bated neurological decline in postmenopausal women
aged 65 years or older. These clinical findings are consist-
ent with our in vitro data demonstrating that MPA antago-
nized 17β-estradiol-induced mechanisms of memory and
neuroprotection. In contrast, progesterone was both neu-
roprotective alone and synergized with 17β-estradiol [22-
25].
Moreover, the estrogen component of ET/HT can affect
study outcomes as well. Earlier trials have revealed a trend
of better cognitive scores from a single estrogen formula-
tion, 17β-estradiol valerate [26-28], than CEE, a complex
formulation of estrogens [29,30]. Although CEE showed
beneficial effects in some prevention model systems, this
complex formulation, extracted from pregnant mares'
urine, contains multiple estrogens, including ones not
secreted by human ovaries, as well as other biologically
active steroids [31]. Whether this complex formulation of
ET/HT, as well as the doses commonly used in clinical
studies, are optimal to provide the maximum neurologi-
cal benefit remains to be determined. Although the full
spectrum of estrogenic components present in CEE has
not yet been resolved, 10 estrogens have been identified
(Fig. 1), including the sulfate esters of the ring B saturated
estrogens (classical estrogens), estrone, 17α-estradiol andBMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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17β-estradiol, and the ring B unsaturated estrogens, equi-
lin, 17α-dihydroequilin, 17β-dihydroequilin, equilenin,
17α-dihydroequilenin, 17β-dihydroequilenin and ∆8,9-
dehydroestrone [31]. Studies have indicated that all these
estrogens bind to estrogen receptor (ER), though with dif-
ferent affinities, and are uterotrophic as demonstrated by
increased uterine weight in rats [31,32].
The current study was undertaken to determine the impact
of the above 10 estrogenic components within CEE on
measures of neuronal viability and survival, at concentra-
tions commensurate with their plasma levels achieved fol-
lowing a single oral dose of 0.625 mg CEE [33].
Subsequently, combinations of neuroprotective estrogens
were assessed to determine whether coadministration of
select estrogenic molecules within CEE were more effica-
cious than single molecule formulations. Primary cultures
of basal forebrain neurons were used due to their vulner-
ability to neurodegeneration in the aging or AD brain
[34,35], and all analyses were conducted with a compara-
tive reference to 17β-estradiol. Further, computer-aided
modeling analyses were conducted to investigate the
potential correlation among the neuroprotective efficacy
of estrogens, their structures and estrogen interactions
with ER.
Results
Select estrogens within CEE are neuroprotective against β-
amyloid25–35-induced toxicity in primary basal forebrain 
neurons
Our earlier work demonstrated that the complex formula-
tion of CEE is significantly protective against β-amyloid25–
35-induced neurotoxicity in primary basal forebrain neu-
rons [15]. To determine which of the estrogenic compo-
nents within CEE exert neuroprotective effects, cultured
basal forebrain neurons were pretreated with test estro-
gens for 4 days at concentrations commensurate with
those detected in plasma following a single oral dose of
0.625 mg CEE followed by exposure to a toxic level of β-
amyloid25–35 (8 µg/ml) for 24 hr. As shown in Table 1,
select estrogens contained within CEE were neuroprotec-
tive against β-amyloid25–35-induced toxic insult. At con-
Chemical structures of test estrogens within CEE Figure 1
Chemical structures of test estrogens within CEE.BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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centrations comparable to plasma levels of estrogens,
17α-estradiol, 17β-estradiol, equilin, equilenin, 17α-
dihydroequilin and ∆8,9-dehydroestrone, each signifi-
cantly reduced the β-amyloid25–35-induced LDH release.
The LDH level from cultures pretreated with estrone or
17β-dihydroequilin was not significantly different com-
pared to β-amyloid25–35 alone-treated cultures (Table 1).
Differential neuroprotective profile with intracellular ATP 
level as the neuronal viability index
Pretreatment with 17β-estradiol, estrone and ∆8,9-dehy-
droestrone, individually, significantly protected neurons
against β-amyloid25–35-induced intracellular ATP decline
(Table 2). Neurons pretreated with equilin had a nonsig-
nificant increase in intracellular ATP level compared to β-
amyloid25–35 alone-treated cultures (Table 2). In contrast,
17α-estradiol, equilenin and 17α-dihydroequilin, each of
which was demonstrated to be neuroprotective by LDH
measurements, were ineffective in protecting basal fore-
brain neurons against β-amyloid25–35-induced ATP
decline (Table 2).
Neuroprotective effects of select estrogens against 
glutamate-induced excitotoxicity
We previously demonstrated that 17β-estradiol, equilin
and ∆8,9-dehydroestrone are neurotrophic in promoting
neurite outgrowth [36,37]. Results of the present study
further indicated that these 3 estrogens were neuroprotec-
tive against LDH release and intracellular ATP decline fol-
lowing compromised neuronal plasma membrane
integrity and mitochondrial function induced by β-
amyloid25–35. We then tested these estrogens for their neu-
roprotective efficacy against excitotoxic insult by 200 µM
glutamate. Estrone was examined as well based on its sig-
nificant effect in preventing the intracellular ATP decline
induced by β-amyloid25–35. Data shown in Table 3 dem-
onstrate that the estrogens, 17β-estradiol, equilin and
∆8,9-dehydroestrone, but not estrone, significantly pro-
tected neurons against neurotoxic glutamate-induced
LDH release. Further analyses of neuronal viability of
intracellular ATP content revealed that none of these
estrogens significantly protected neurons against excito-
toxic glutamate-induced ATP decline (Table 4).
Neuroprotective effects of select estrogens based on MTT 
reduction measurements
To further determine the impact of select estrogens on
neuronal metabolic capability, the mitochondrial conver-
sion of MTT to formazan crystals by metabolically active
neurons was measured in cultures pretreated with estro-
gens followed by exposure to excitotoxic glutamate. Select
neuroprotective estrogens determined by LDH measure-
ments as shown in Table 1, as well as two other estrogens,
17α-dihydroequilenin and 17β-dihydroequilenin, that
were not tested previously, were evaluated. Both LDH and
MTT assay were conducted on cultures from the same
plate (Table 5). Results from the LDH measurements were
consistent with the previous data, indicating that estro-
gens, 17α-estradiol, 17β-estradiol, equilin, equilenin,
17α-dihydroequilin, and ∆8,9-dehydroestrone were neu-
roprotective against neuronal membrane damage induced
by exposure to both β-amyloid25–35 and glutamate (Table
1 and 5). Both 17α-dihydroequilenin and 17β-dihy-
droequilenin significantly reduced the glutamate-induced
LDH release as well. Consistent with the results from ATP
analysis, none of the estrogens at the test concentrations
Table 2: Efficacy of select estrogens within CEE to sustain the 
intracellular ATP level following exposure to β-amyloid25–35 in 
basal forebrain neurons. Neuronal cultures were pretreated with 
indicated estrogens for 4 days followed by a 24 hr exposure to 8 
µg/ml β-amyloid25–35. The culture medium was replaced and 
cultures were allowed to incubate for an additional 24 hr 
followed by determination of the intracellular ATP level. Data 
are represented as mean ± SEM (n = 7 – 24 from 3 separate 
experiments). ** P < 0.01 and *** P < 0.001 compared to β-
amyloid25–35 alone-treated cultures.
Treatment 
(pg/ml)
ATP Level 
(% of β-amyloid25–35 alone group)
Control 203.37 ± 11.67***
β-amyloid25–35 alone 100.00 ± 2.07
17α-estradiol (10) 103.83 ± 3.76
17β-estradiol (10) 131.32 ± 4.56**
Equilin (1000) 114.58 ± 3.56
Equilenin (300) 96.44 ± 4.07
17α-dihydroequilin (1000) 110.00 ± 2.75
17β-dihydroequilin (40) 110.75 ± 2.46
Estrone (5000) 128.84 ± 4.14**
∆8,9-dehydroestrone (300) 125.05 ± 1.42**
Table 1: Efficacy of select estrogens within CEE to reduce LDH 
release following exposure to β-amyloid25–35 in basal forebrain 
neurons. Neuronal cultures were pretreated with indicated 
estrogens for 4 days followed by a 24 hr exposure to 8 µg/ml β-
amyloid25–35. The culture medium was replaced and cultures 
were allowed to incubate for an additional 24 hr followed by 
determination of LDH release into the medium. Data are 
represented as mean ± SEM (n = 7 – 24 from 3 separate 
experiments). ** P < 0.01 and *** P < 0.001 compared to β-
amyloid25–35 alone-treated cultures.
Treatment 
(pg/ml)
LDH Release 
(% of β-amyloid25–35 alone group)
Control 36.11 ± 1.60***
β-amyloid25–35 alone 100.00 ± 2.26
17α-estradiol (10) 86.62 ± 2.99**
17β-estradiol (10) 84.20 ± 1.47***
Equilin (1000) 89.01 ± 1.74**
Equilenin (300) 81.49 ± 3.06***
17α-dihydroequilin (1000) 89.96 ± 3.88**
17β-dihydroequilin (40) 101.53 ± 2.00
Estrone (5000) 99.33 ± 4.43
∆8,9-dehydroestrone (300) 85.82 ± 2.07***BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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protected neurons against the glutamate-induced decline
of metabolic activity in basal forebrain neurons.
Coadministration of select neuroprotective estrogens 
exerts greater efficacy against neurotoxic insult
17β-Estradiol, equilin and ∆8,9-dehydroestrone, which
were effective in protecting basal forebrain neurons
against both β-amyloid25–35 and glutamate-induced dam-
age to membrane integrity, as well as β-amyloid25–35-
induced decline in mitochondrial function, were further
evaluated for their neuroprotective efficacy when coad-
ministered in cultured neurons. Results shown in Fig. 2A
demonstrate that the LDH release from cultures pretreated
with combinations of two out of these three estrogens
were not significantly different from cultures pretreated
with single estrogens. However, all three combinations
significantly protected neurons against intracellular ATP
decline compared to either glutamate alone-treated cul-
tures or cultures pretreated with single estrogens (Fig. 2B).
These data indicate that greater neuroprotective efficacy
could be achieved by the coadministration of those neu-
roprotective estrogens at the concentrations consistent
with their plasma levels achieved following an oral
administration of 0.625 mg of CEE.
Correlation between the interactions with ER and the 
neuroprotective profile of estrogen analogues
To gain insights into the intrinsic relationship between
the estrogen structures and their neuroprotective activi-
ties, we computationally simulated the interactions of 4
representative estrogens with the ligand binding site of
ER. In light of our previous finding of equivalent contri-
bution of ER subtypes, α and β, to estrogen neuroprotec-
tion, we used ERα as the docking target in this analysis.
Three estrogens, 17β-estradiol, equilin and ∆8,9-dehy-
droestrone, consistently and significantly protected basal
Table 5: Efficacy of select estrogens within CEE to reduce LDH release and sustain MTT reduction following exposure to excitotoxic 
glutamate in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 5 min 
exposure to 200 µM glutamate. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr 
followed by determination of LDH release into the medium and MTT reduction. Data are represented as mean ± SEM (n = 17 – 33 
from 3 experiments). * P < 0.05, ** P < 0.01 and *** P < 0.001 compared to glutamate alone-treated cultures.
Treatment (pg/ml) LDH Release (% of glutamate alone group) MTT Reduction (% of glutamate alone group)
Control 41.59 ± 2.85*** 194.49 ± 3.52***
Glutamate alone 100.00 ± 1.25 100.00 ± 1.51
17α-estradiol (10) 83.03 ± 1.91** 98.06 ± 1.39
17β-estradiol (10) 92.29 ± 1.91** 98.81 ± 1.93
Equilin (1000) 86.37 ± 2.19** 105.76 ± 3.36
Equilenin (300) 88.00 ± 2.55** 103.62 ± 1.86
17α-dihydroequilin (1000) 90.68 ± 2.21** 102.22 ± 2.25
17α-dihydroequilenin (27) 84.74 ± 3.02** 91.10 ± 5.63
17β-dihydroequilenin (27) 90.87 ± 2.99* 113.17 ± 3.65
∆8,9-dehydroestrone (300) 86.69 ± 2.20** 102.88 ± 2.71
Table 3: Efficacy of select estrogens within CEE to reduce LDH 
release following exposure to excitotoxic glutamate in basal 
forebrain neurons. Neuronal cultures were pretreated with 
indicated estrogens for 4 days followed by a 5 min exposure to 
200 µM glutamate. The culture medium was replaced and 
cultures were allowed to incubate for an additional 24 hr 
followed by determination of LDH release into the medium. 
Data are represented as mean ± SEM (n = 11 – 14 from 3 
experiments). ** P < 0.01 and *** P < 0.001 compared to 
glutamate alone-treated cultures.
Treatment 
(pg/ml)
LDH Release 
(% of glutamate alone group)
Control 47.49 ± 2.69***
Glutamate alone 100.00 ± 2.89
17β-estradiol (10) 57.55 ± 3.00**
Equilin (1000) 64.02 ± 3.03**
Estrone (5000) 85.46 ± 3.22
∆8,9-dehydroestrone (300) 66.05 ± 2.74**
Table 4: Efficacy of select estrogens within CEE to sustain the 
intracellular ATP level following exposure to excitotoxic 
glutamate in basal forebrain neurons. Neuronal cultures were 
pretreated with indicated estrogens for 4 days followed by a 5 
min exposure to 200 µM glutamate. The culture medium was 
replaced and cultures were allowed to incubate for an additional 
24 hr followed by determination of the intracellular ATP level. 
Data are represented as mean ± SEM (n = 11 – 14 from 3 
experiments). ** P < 0.01 compared to glutamate alone-treated 
cultures.
Treatment 
(pg/ml)
ATP Level 
(% of glutamate alone group)
Control 128.72 ± 4.21**
Glutamate alone 100.00 ± 1.50
17β-estradiol (10) 109.38 ± 2.91
Equilin (1000) 108.44 ± 1.86
Estrone (5000) 93.41 ± 3.85
∆8,9-dehydroestrone (300) 111.80 ± 4.51BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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forebrain neurons against neurotoxic insults, while
estrone was ineffective in most measurements. Results of
molecular docking revealed that all 4 estrogens bind to
ERα in a similar binding mode, with a hydrogen bond
interaction occurring in all complexes between the atom
OE2 of the residue Glu 353 in the binding site of the
receptor and the hydrogen atom of the phenol group in
the A ring of estrogens (Fig. 3). Rank order of the intermo-
lecular energy, a total of both the van der Waals (VDW)
and electrostatic energy between estrogens and ERα, indi-
cated that 17β-estradiol > equilin and ∆8,9-dehy-
droestrone > estrone (Table 6), which is parallel to their
neuroprotective activities. In addition to the hydrogen
bonding derived from the A ring phenol group which
characterizes all estrogens regardless of their neuroprotec-
tive efficacy, an additional hydrogen bond interaction
occurs between the atom ND1 of the residue His 524 and
the hydroxyl group in the D ring of 17β-estradiol, serving
as a main contributor to the intermolecular interaction
that accounts for the high binding affinity of 17β-estradiol
in comparison to the other 3 estrogens. A double bond in
the B ring of the structures of equilin and ∆8,9-dehy-
droestrone but absent in estrone enhances the VDW inter-
actions of estrogens with the vicinal residues situated in
the binding site of the receptor. These analyses indicate
that intermolecular hydrogen bond interactions are essen-
tial for estrogen binding to ER, and the steroidal skeletal
structural change contributes to the differential binding
affinities of estrogens as well. In addition, the neuropro-
tective efficacy of estrogens in primary basal forebrain
neurons correlates to their interactions with ER. These
data provide a computational chemistry platform upon
which to predict the neuroprotective efficacy of estrogen
molecules.
Discussion
The neuroprotective profile of select estrogens within CEE 
that are suggestive for clinical use
Taken together, the present study demonstrates that select
estrogenic components within CEE are protective against
neurodegenerative insults induced by β-amyloid25–35 and
excitotoxic glutamate in primary basal forebrain neurons.
Results of these analyses indicate that 3 of the 10 estro-
gens tested, 17β-estradiol, equilin and ∆8,9-dehy-
droestrone, were consistently neuroprotective against β-
amyloid25–35-induced decline in membrane integrity and
mitochondrial function. Further, our analyses indicate
that coadministration of these neuroprotective estrogens
can enhance the magnitude of their neuroprotective effi-
cacy as evidenced by the observation that the above 3
estrogens, when used individually, were ineffective at the
plasma dose whereas these same estrogens, when used in
combination, were protective against excitotoxic gluta-
mate-induced neuronal compromise of both the plasma
membrane and mitochondrial function. The neuroprotec-
tive effects of combined estrogens could be synergistic in
instances where a single estrogen exhibits no impact on
neuronal viability, while the combined use of several
estrogens induces a significant increase of neuronal viabil-
ity. Another possibility is that since the concentrations of
estrogens used in the present study were very low, consist-
ent with the therapeutic plasma levels of these estrogens
following a single oral dose of 0.625 mg CEE, the capacity
of multiple estrogens to induce significant increase in
markers of neuronal viability may simply be a threshold
concentration issue. The low concentration of a single
estrogen was not sufficient to increase neuronal defense
mechanisms whereas a combination of multiple estro-
gens reached threshold concentration. In addition to the
threshold concentration issue, the estrogen specificity
requirement impacts estrogen efficacy as well, since not all
estrogens were proved to be neuroprotective based on a
quite sensitive measurement of LDH release.
Overall, the present study indicates that a combination of
select neuroprotective estrogens at low concentrations
could provide better therapeutic potential than adminis-
tering a single estrogen. A formulation composed of both
neuroprotective and non-protective estrogenic compo-
nents may result in a compromised outcome through a
competitive mechanism with multiple estrogens of vary-
ing efficacy competing for the same site of action with var-
ying degrees of activation capability in the brain. Data
from the present study suggest that, instead of using a
complex formulation of estrogens with varying degrees of
efficacy in the brain, using a formulation that is selectively
efficacious for the brain could yield greater therapeutic
benefit to promote neurological health and prevent neu-
rodegeneration in postmenopausal women.
Different biochemical markers based on different cellular 
processes may yield different responses
An important issue emerging from the present study
relates to the biochemical markers used to assess the neu-
ronal viability. For the LDH release assay, since the extra-
cellular LDH remains stable for days, the magnitude of
relative release of LDH correlates in linear fashion with
the number of damaged neurons in the culture. The LDH
release assay has been demonstrated to be a reliable indi-
cator of cellular plasma membrane integrity and proved to
be a consistent marker for estrogen efficacy in protecting
neuronal membrane against neurotoxic insults in neurons
[38]. The ATP and MTT assays are considered reliable indi-
cators of cellular metabolic activity dependent upon mito-
chondrial functional integrity determined by the
measurements of the cellular mitochondrial energy utili-
zation and respiratory chain activity, respectively. In the
present study, select estrogens that were neuroprotective
against LDH release induced by neurotoxic β-amyloid25–
35 or excitotoxic glutamate were ineffective in promotingBMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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neuronal metabolic integrity, indicating that neuronal
membrane damage may be more easily protected and
repaired than damage to neuronal mitochondrial func-
tion. The combined use of these select estrogens led to an
enhanced neuroprotective efficacy, indicating that the
neuroprotective efficacy exhibited by multiple estrogens
could reach the threshold concentration sufficient for the
maintenance of neuronal mitochondrial function. These
analyses implicate a molecule that can protect neurons
against plasma membrane damage reflected by the meas-
urement of the LDH level in the culture medium does not
necessarily have the same potential to maintain or reduce
the damage to the cellular mitochondrial function. Fur-
ther, these data suggest that one cannot expect these bio-
chemical neuroprotective indexes to have equivalent
responses to a chemical molecule because they are bio-
chemical markers of distinct cellular processes. Therefore,
investigations using multiple biochemical neuroprotec-
tive markers based on different cellular processes are nec-
essary in order to determine the overall neuroprotective
potential of an estrogenic molecule against the toxic
insults in neurons.
In addition, it should be noted that the profile of neuro-
protective efficacy of test estrogens demonstrated in the
present study is associated with the therapeutic plasma
levels of these estrogens achieved following a single oral
dose of 0.625 mg CEE. For example, although pretreat-
ment with 10 pg/ml of 17β-estradiol was effective in pro-
tecting neurons against β-amyloid25–35-induced
intracellular ATP decline, an indication of neuronal mito-
chondrial dysfunction, such protection was not signifi-
cant in neurons exposed to excitotoxic glutamate. One
possible explanation is that compromise of neuronal
mitochondrial function resulting from a slowly degenera-
tive process, such as β-amyloid exposure, allows for cellu-
Superimposition of 3D complex models of ERα with 17β-estradiol (dark red; PDB ID: 1ERE), equilin (blue), ∆8,9-dehy- droestrone (green) and estrone (purple) Figure 3
Superimposition of 3D complex models of ERα with 17β-estradiol (dark red; PDB ID: 1ERE), equilin (blue), 
∆8,9-dehydroestrone (green) and estrone (purple). Estrogen receptors are represented as alpha carbon traces. Hydro-
gen bonds are labeled in dashed green lines. The comparison of these complex structures revealed that the four estrogens bind 
to ERα in a similar binding mode, with a hydrogen bond interaction occurring between the atom OE2 of the residue Glu 353 in 
the binding site of the receptor and the hydrogen atom of the phenol group in the A ring of estrogens. An additional hydrogen 
bond interaction occurs between the atom ND1 of the residue His 524 and the hydroxyl group in the D ring of 17β-estradiol. 
Image was generated using Accelrys InsightII 2000.BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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Efficacy of combined administration of select neuroprotective estrogens within CEE against glutamate-induced toxicity in basal  forebrain neurons Figure 2
Efficacy of combined administration of select neuroprotective estrogens within CEE against glutamate-
induced toxicity in basal forebrain neurons. Three-day-old basal forebrain neurons were pretreated with either single 
estrogens or combinations of estrogens followed by a 5 min exposure to 200 µM glutamate. Both LDH release into the 
medium and the intracellular ATP level were measured 24 hr later. Data are represented as mean ± SEM (n = 8 – 12 from 3 
experiments). * P < 0.05, ** P < 0.01 and *** P < 0.001 compared to glutamate alone-treated cultures.BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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lar neuroprotective adaptations following β-amyloid
exposure, whereas a rapid neurodegenerative insult, such
as excitotoxic glutamate exposure, does not allow for
upregulation of neuronal defense mechanisms but
instead relies solely on existing levels of defense mecha-
nisms. Consistent with this hypothesis, both β-amyloid
and excitotoxic glutamate-induced neurodegeneration are
associated with calcium influx, however the temporal pat-
tern and magnitude of the calcium rise are quite different.
β-Amyloid exposure induces a slow and modest rise in
intracellular calcium whereas excitotoxic glutamate
induces a rapid and robust rise in intracellular calcium
[39]. However, the calcium-mediated neuronal dysfunc-
tion in response to excitotoxic glutamate can be overcome
with either the combined use of multiple estrogens, as
demonstrated in the present study, or the administration
of a higher concentration of a single estrogen, such as 17β-
estradiol, as evidenced by our previous studies, in which
pretreatment of neurons with 10 ng/ml of 17β-estradiol
induced a sustained mitochondrial respiration in the pres-
ence of high calcium [40,41].
Structure and neuroprotective activity predict modes of 
actions by estrogens
Analyses of the chemical structures of both neuroprotec-
tive and non-neuroprotective estrogens within CEE indi-
cate that both types of estrogens contain a phenolic A ring.
Thus, it raises a question with respect to the necessity of
this structural moiety in allowing estrogenic neuroprotec-
tion in the brain. A representative classical nuclear ER-
independent mechanism proposed by Simpkins and col-
leagues suggests that estrogenic neuroprotection can be
conferred by a phenolic A ring in the steroid structures of
estrogens, which serves as a free-radical scavenging moiety
by donating a proton that saturates neurodegenerative
agent-induced unpaired reactive oxygen species [42-44].
An example in support of this hypothesis is 17α-estradiol,
which is 100-fold less potent than its optical isomer, 17β-
estradiol, in inducing classical estrogenic actions includ-
ing uterotrophic stimulation and MCF7 cell proliferation,
is as potent and efficacious as 17β-estradiol in a number
of neuroprotection assays [44]. Our present study pro-
vided further evidence for 17α-estradiol's neuroprotective
potency. Further, Simpkins et al demonstrated that in the
hippocampal HT-22 cell line, a number of estrogens syn-
ergistically interacted with glutathione to increase the
neuroprotective potency of estrogens [45]. The interaction
between glutathione and endogenous estrogen 17β-estra-
diol-induced neuroprotection was also found in SK-N-SH
human neuroblastoma cells and primary cortical neurons
[46]. In addition, Simpkins and colleagues indicated that
17β-estradiol-induced promotion of neuronal survival in
SK-N-SH cells is associated with the increased activity of
neuronal nitric oxide synthase [47]. Other potential
mechanisms of actions including estrogen interactions
with signal transduction pathways and induction of mito-
chondrion-localized anti-apoptotic proteins have also
been associated with the neuroprotective effects of phe-
nolic A ring estrogens [48,49].
An alternative to an ER-independent mechanism of estro-
gen-induced neuroprotective functions is an ER subtype-
dependent mechanism. ERα and ERβ are expressed in the
brain with differential abundance in different brain
regions [50]. Multiple factors modulate the relative contri-
bution of the two ER subtypes to the outcomes of neuro-
protection including the type of model system, the brain
region and the cell type under investigation, and even the
administered dose of estrogens [51]. For instance, in an in
vivo ischemia model, Dubal and colleagues demonstrated
that ERα, but not ERβ, is required for the protective effects
of 17β-estradiol against ischemia-induced injury [52]. In
contrast, Sawada and Shimohama showed that ERβ medi-
ates estrogen neuroprotection in mesencephalon
dopaminergic neurons that exclusively express ERβ [53].
Recent studies from Dorsa and colleagues demonstrated
that both ERα and ERβ are involved in mediating estrogen
neuroprotection against β-amyloid-induced toxicity and
oxidative stress in HT-22 cells that stably express either
ERα or ERβ, and that this ER-mediated neuroprotection
requires the activation of the MAP kinase pathway
[54,55]. Studies from our laboratory using ER subtype-
selective agonists further indicate a near equivalent contri-
bution of ERα and ERβ to estrogen-induced neuroprotec-
tion and upregulation of the neuroprotective gene, Bcl-2,
in primary hippocampal neurons [38].
Table 6: Intermolecular interaction between estrogens and ERα. avan der Waals energy; belectrostatic energy.
Estrogens Intermolecular Energy H-Bond Distance
VDWa Electb Total d1 (Glu353:OE2) d2 (His524:ND1)
17β-estradiol -55.06 -20.43 -75.48 1.56 2.02
Equilin -58.17 -12.33 -70.49 1.71
∆8,9-dehydroestrone -58.40 -13.09 -71.49 1.67
Estrone -55.92 -12.76 -68.68 1.66BMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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We speculate that estrogen induction of neuroprotection
can be mediated by either ER-independent or ER-depend-
ent pathways depending upon the concentration of estro-
gen administered. An ER-independent anti-oxidant
property is much likely the dominant factor contributing
to estrogen neuroprotection at suprapharmacological
doses (µM range). In contrast, at a relatively low therapeu-
tically relevant concentration range (pM or nM range), an
ER-dependent signalling pathway is likely to be the main
mediator of estrogen induction of neuroprotection [56].
Our analysis revealed that estrone at 5 nM was ineffective
in enhancing neuronal defense systems in response to
neurotoxic insults. In analyses by Bae and colleagues, 10–
100 µM estrone protected against oxidative stress-induced
cell death in mouse cortical neurons, whereas, estrone at
a concentration of less than 3 µM was ineffective.
Together, these data indicate that estrone is an ineffective
activator of the brain ER and the associated signalling
events required for estrogen neuroprotection at a low ther-
apeutically relevant concentration, whereas, at a suprap-
harmacological dose, estrone can function as an effective
antioxidant.
Our investigation of the intermolecular interactions of
estrogens with ERα as well as the correlation between the
estrogen structures with their neuroprotective activities at
low concentrations comparable to their plasma levels
revealed that although 4 representative estrogen ana-
logues, 17β-estradiol, equilin, ∆8,9-dehydroestrone and
estrone, bind to ERα in a similar binding mode in both
conformation and orientation, their structural small vari-
ances still result in slightly different intermolecular ener-
gies with ERα, which in turn could impact their
neuroprotective efficacy as evidenced by the parallel coin-
cidence between the intermolecular energies among estro-
gens and their neuroprotective activities. Furthermore, we
found that the presence of a phenolic A ring did not pre-
dict which estrogens, at least at a relatively low therapeutic
concentration, would be full neuroprotective estrogens as
multiple estrogens represented by estrone which was not
protective in most conditions but contains a phenolic A
ring. This suggests that the presence of a phenolic A ring
in estrogens may be essential, but not entirely sufficient
for estrogen-inducible neuroprotection at both the cellu-
lar plasma membrane and mitochondrial function medi-
ated by an ER-dependent signalling pathway. In
comparison, the phenolic A ring may be the crucial struc-
tural feature for allowing induction of neuroprotection by
a relatively high concentration of estrogen through its
anti-oxidant property. Further, we hypothesize that estro-
genic neuroprotection is irrespective of activation of clas-
sical nuclear ERs but may be mediated through a non-
nuclear ER-mediated signalling pathway, as supported by
a increasing number of studies for a membrane-localized
ER in regulating estrogen functions in neurons [50].
Conclusion
In conclusion, the present study demonstrates that select,
not all, estrogens within the complex formulation of CEE
at concentrations commensurate with their plasma levels
achieved after an oral administration of 0.625 mg CEE in
women, contribute to its neuroprotective efficacy. Coad-
ministration of select neuroprotective estrogens can lead
to a greater magnitude of neuroprotection of neuronal
plasma membrane and mitochondrial function. These
data provide important insights into the rational design
and development of a composition of estrogen therapy to
alleviate climacteric symptoms, promote neurological
health and prevent age-related neurodegeneration, such
as AD, in postmenopausal women. A more effective and
safer brain-selective estrogen formulation than CEE could
be developed through a thorough analysis of the neuro-
protective efficacy of those estrogens of interest under
physiological conditions.
Methods
Neuronal cultures
The use of animals was approved by the Institutional Ani-
mal Care and Use Committee (IACUC) at the University
of Southern California. Primary cultures of basal fore-
brain neurons were obtained from embryonic day 18
(E18d) Sprague-Dawley rat fetuses as previously described
[15,36]. Briefly, after dissection from the brains of the rat
fetuses, the septal basal forebrain was treated with 0.02%
trypsin in Hank's balanced saline solution (HBSS, 137
mM NaCl, 5.4 mM KCl, 0.4 mM KH2PO4, 0.34 mM
Na2HPO4·7H2O ,  1 0 . 0  m M  g l u c o s e ,  a n d  1 0 . 0  m M
HEPES) for 5 min at 37°C and dissociated by repeated
passage through a series of fire-polished constricted Pas-
teur pipettes. Approximately 105 neurons/ml were plated
onto poly-D-lysine (10 µg/ml)-coated 24-well and 96-
well culture plates for biochemical analyses. Neurons
were grown in a phenol red-free Neurobasal medium
(NBM, Invitrogen) supplemented with B27, 5 U/ml peni-
cillin, 5 µg/ml streptomycin, 0.5 mM glutamine, and 25
µM glutamate at 37°C in a humidified 10% CO2 atmos-
phere for the first 3 days and NBM without glutamate
afterwards. Cultures grown in serum-free NBM yield
approximately 99.5% neurons and 0.05% glia cells.
Estrogen treatment
The estrogens were tested at concentrations commensu-
rate with their plasma levels achieved following a single
oral dose of 0.625 mg CEE, including estrone (5000 pg/
ml), 17α-estradiol (10 pg/ml), 17β-estradiol (10 pg/ml),
equilin (1000 pg/ml), 17α-dihydroequilin (1000 pg/ml),
17β-dihydroequilin (40 pg/ml), equilenin (300 pg/ml),
17α-dihydroequilenin (27 pg/ml), 17β-dihydroequilenin
(27 pg/ml) and ∆8,9-dehydroestrone (300 pg/ml). All
estrogens were purchased from Steraloids with the excep-
tion of 17α-dihydroequilenin, 17β-dihydroequilenin andBMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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∆8,9-dehydroestrone, which were gifts from Dr. Michael
Dey and Dr. Richard Lyttle of Wyeth-Ayerst Laboratories.
The chemical structures of these estrogens are listed in Fig.
1. A vehicle alone-treated control group and a neurotoxin
alone (β-amyloid25–35 or glutamate)-treated group were
included in all experiments.
β-Amyloid25–35 exposure
β-Amyloid25–35 purchased from Bachem was dissolved in
sterile distilled water at a concentration of 1 mg/ml as a
stock solution. This stock was aliquoted and stored at -
20°C. Three-day-old basal forebrain neurons were pre-
treated with test estrogens for 4 days followed by exposure
to freshly prepared 8 µg/ml β-amyloid25–35 in NBM in the
presence of test estrogens for 24 hr at 37°C. Following this
exposure, the culture medium was replaced with fresh β-
amyloid25–35-free NBM containing test estrogens. Cultures
were returned to the culture incubator and allowed to
incubate for additional 24 hr prior to cell viability meas-
urements on the following day.
Glutamate exposure
Three-day-old basal forebrain neurons were pretreated
with test estrogens for 4 days followed by exposure to 200
µM glutamate for 5 min at room temperature in HEPES-
buffered saline solution (HBS) containing 100 mM NaCl,
2.0 mM KCl, 2.5 mM CaCl2, 1.0 mM MgSO4, 1.0 mM
NaH2PO4, 4.2 mM NaHCO3, 10.0 mM glucose and 12.5
mM HEPES. Immediately following glutamate exposure,
cultures were washed once with HBS and replaced with
fresh NBM containing test estrogens. Cultures were
returned to the culture incubator and allowed to incubate
for an additional 24 hr prior to cell viability measure-
ments on the following day.
LDH assay
Lactate dehydrogenase (LDH) is a stable cytoplasmic
enzyme present in all cells including neurons. It is rapidly
released into the cell culture supernatant when the cell
plasma membrane is damaged. Thus, the LDH level in the
culture medium is a reliable biochemical index for neuro-
nal plasma membrane damage. In this study, LDH release
from the cytosol of damaged neurons into the culture
medium following β-amyloid25–35 or glutamate exposure
was measured using a Cytotoxicity Detection Assay (Boe-
hringer Mannheim Biochemicals), which determines the
LDH activity in the culture medium to enzymatically con-
vert the lactate and NAD+ to pyruvate and NADH. The
tetrazolium salt produced in the enzymatic reaction was
then reduced to red formazan in the presence of H+,
thereby allowing a colormetric detection for neuronal
membrane integrity.
ATP assay
Intracellular ATP (adenosine triphosphate) levels were
determined by a luciferin/luciferase-based method with a
Bioluminescent Assay (Sigma-Aldrich), which uses ATP, a
required co-factor of the luciferase reaction, producing
oxyluciferin and releasing energy in the form of lumines-
cence that is proportional to the amount of ATP present,
which further signals the presence of metabolically active
cells. After the culture medium supernatant was taken for
the LDH assay and the rest of the medium was aspirated
off, the ATP-releasing reagent was added to the culture
plate to solubilize cellular membrane which allowed the
release of intracellular ATP into the medium. The gener-
ated luminescence through the luciferase reaction was
quantified with a TD-20e TURNER luminometer.
MTT assay
Neuronal metabolic viability was further determined
using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide, Boehringer Mannheim Bio-
chemicals) assay, which measures the enzymatic activity
of the cellular mitochondrial respiratory chain through
the conversion of yellow MTT to a purple formazan crystal
by metabolically active cells. MTT was added to the cul-
ture plate at a final concentration of 0.5 mg/ml and incu-
bated at 37°C for 4 hr. The reaction was stopped by the
addition of 1 mM HCl in 10% SDS. Formazan crystals
were dissolved overnight and absorption was measured
with a spectrophotometer at 575 nm.
Molecular modelling
All the calculations were performed on a SGI Octane
graphical workstation equipped with the IRIX 6.5 operat-
ing system (Silicon Graphics Inc.) using the molecular
modeling software package InsightII 2000 (Accelrys Inc.).
The 3D structures of estrogens were constructed and
energy minimized via both molecular mechanics and
dynamics simulation. The binding modes (position and
orientation) of estrogens in the ligand binding site of ER
were predefined by superimposing the optimized 3D
structures of estrogens and the crystallographic structure
of 17β-estradiol bound with its cognate receptor [58].
Then the structure of 17β-estradiol was removed from the
complex and the remaining objects were associated as a
new assembly. Following the hydrogenation of the system
based on a target pH of 7.0, the resultant complex, which
served as the initial binding model of estrogens in com-
plex with ER, was energetically optimized by the Discover
calculation under a consistent-valence forcefield (CVFF).
The initial estrogen-ER complex system was first energeti-
cally minimized with the receptor atoms fixed by consec-
utively executing 800 steps of steepest descents (SD)
minimization and then 500 steps of conjugate gradients
(CG) minimization. The refined complex system was then
relaxed by removing the constraint on the residues withinBMC Neuroscience 2006, 7:24 http://www.biomedcentral.com/1471-2202/7/24
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7 Å of estrogens and further energetically optimized by
applying 800 steps of SD and 500 steps of CG, followed
by a 20 ps molecular dynamics simulation at 300 K. Con-
formations were written to a history file every 1 ps and the
collected conformations underwent further molecular
mechanics minimization by performing 800 steps of SD
and 500 steps of CG. The yielded estrogen bound confor-
mation with the lowest energy was chosen as the final
binding solution.
Data analyses
Results from LDH, ATP and MTT assay are normalized
against the data obtained from neurotoxin alone-treated
cultures. Data are presented as the mean ± SEM derived
from at lease three separate experiments. Statistically sig-
nificant differences between groups were determined by a
one-way analysis of variance (ANOVA) followed by a
Newman-Keuls post hoc analysis.
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